|
| Press Releases |
|
 |
|
| Tuesday, June 21, 2022 |
|
|
The Mechanism of Action of SinoMab's Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S. |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-listed biopharmaceutical company dedicated to the research, development more info >> |
|
| Wednesday, June 15, 2022 |
|
|
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S. |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Thursday, June 9, 2022 |
|
|
SinoMab Announces IND Application for SN1011 Accepted by NMPA CDE |
| SinoMab BioScience Limited ("SinoMab"; 3681.HK), a Hong Kong-based biopharmaceutical company, an Investigational New Drug application (IND, for neuromyelitis optica spectrum disorder (NMOSD)) for SN1011 has been filed with and accepted by the Center for Drug Evaluation (the CDE) of the National Medical Products Administration of China (NMPA). more info >> |
|
| Wednesday, April 20, 2022 |
|
|
SinoMab Announces IND APPLICATION FOR SN1011 APPROVED BY NMPA |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development more info >> |
|
| Monday, March 14, 2022 |
|
|
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Approved by FDA |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Thursday, February 17, 2022 |
|
|
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Monday, February 7, 2022 |
|
|
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 21 January 2022, more info >> |
|
| Tuesday, January 11, 2022 |
|
|
SinoMab Awarded the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies" |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Tuesday, November 30, 2021 |
|
|
SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03 |
| SinoMab BioScience Limited ("SinoMab", or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Friday, November 26, 2021 |
|
|
SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health |
| SinoMab BioScience Limited ("SinoMab", or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Mitsubishi Power Receives Contract for Large-Scale GTCC Project with 2,800 MW Total Output for Taiwan's Tung Hsiao Power Plant
Sept 5, 2025 21:47 JST
|
|
|
Hitachi announces historic $1 billion USD manufacturing investment to power America's energy future through production of critical grid infrastructure 
Sept 5, 2025 21:00 JST
|
|
|
Fourth Paradigm announces 2025 interim results
Sept 5, 2025 18:25 HKT/SGT
|
|
|
Asia Unicorn Forum Releases 2024 Report: China, India, Israel Top Asian Unicorn Rankings
Sept 5, 2025 11:03 HKT/SGT
|
|
|
CBL International Reports 1H 2025 Results Highlighting Strong Biofuel Growth, Reduced Net Loss, and Improved Gross Profit Margin
Sept 5, 2025 10:36 HKT/SGT
|
|
|
NEC participates in Locked Shields 2025 hosted by the NATO Cooperative Cyber Defence Centre of Excellence
Sept 5, 2025 11:20 JST
|
|
|
LOLC Advanced Tech and Corsair Group Join Forces to Transform Waste into Fuel in Sri Lanka
Sept 5, 2025 07:00 HKT/SGT
|
|
|
TANAKA Announces Executive Appointment
Sept 5, 2025 3:00 JST
|
|
|
The MOU Signing Ceremony cum Seminar Titled "A New Horizon in Film & TV Trading: Web3 x DMP - Reshaping the Cross-Industry Supply Chain" Hosted by eBRAM Concludes Successfully
Sept 4, 2025 22:35 HKT/SGT
|
|
|
Magnum Opus Resorts Launches International Architectural Design Competition for Iconic Costa Rica Retreat
Sept 4, 2025 21:07 HKT/SGT
|
|
|
U.S. Polo Assn. Celebrates Historic Title Sponsorship of 2025 Pacific Coast Open at Santa Barbara Polo & Racquet Club
Sept 4, 2025 19:00 HKT/SGT
|
|
|
HKTDC Export Confidence Index: 3Q25; Exporter optimism rises as global trade tension falls
Sept 4, 2025 17:10 HKT/SGT
|
|
|
Zhejiang Expressway Absorbs and Merges with Oceanking Development: Establishing Dual A+H Platform to Boost Share Price
Sept 4, 2025 15:02 HKT/SGT
|
|
|
Fashion Hong Kong celebrates 10th anniversary, Four local brands present 'A Decade in Design: What is Seen? What is Felt?'
Sept 4, 2025 13:47 HKT/SGT
|
|
|
Honda to Begin Sales of All-new Prelude
Sept 4, 2025 13:20 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
